📰 Genoscience Pharma News
Page 3 - Genoscience Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genoscience Pharma. Real-time updates on events, politics, business and more.
September 13, 2022
Lille (France), Cambridge (Massachusetts, United States), September 13, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical comp
August 1, 2022
Genfit (NASDAQ:GNFT – Get Rating) and Renovacor (NYSE:RCOR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Valuation and Earnings This table compares Genfit and Renovacor’s top-line revenue, […]
July 18, 2022
/PRNewswire/ -- DelveInsights Hepatocellular Carcinoma Market Insights report proffers a detailed comprehension of the Hepatocellular Carcinoma market size by...
July 8, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
June 19, 2022
Genfit (NASDAQ:GNFT – Get Rating) and Kiromic BioPharma (NASDAQ:KRBP – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings. Risk and Volatility Genfit has a beta of 1.36, suggesting […]
December 17, 2021
Ipsen is paying €120 million up front to acquire global rights to elafibranor, a Genfit drug that fell short as a treatment for NASH, but is currently in Phase 3 testing in another liver disease, primary biliary cholangitis. Meanwhile, Genfit is adding an early-stage drug candidate to its own pipeline via a separate transaction.